Abstract：Objective To analyze the correlation between serum ferritin(SF) as well as serum sclerostin(Sost) levels and bone mineral density(BMD) in elderly male patients with type 2 diabetes mellitus(T2DM).Methods The dual-energy X-ray bone densitometers(Challenger，DMS，France) manufactured in France was adopted to determine the BMD in the second to the fourth lumbar vertebra(L2～4 ) in anteroposterior position，the left femoral neck，the Ward’s triangle area as well as the greater trochanter region of the 48 cases of elderly male T2DM patients with the age of above 70-year-old；in addition，the SF，Sost and glycosylated hemoglobin(HbA1c) levels were determined；then the same measuring method was utilized to measure the same indicators of the 48 cases of elderly male non-T2DM patients with the age of above 70-year-old(the control group)；and retrospective statistical analysis was conducted to analyze the correlation between the SF as well as Sost levels and the BMD in each part.Results Firstly，the Sost(325.56±123.63)pg/mL and SF(565.72 ±237.63)ng/mL levels in the T2DM group were remarkably higher than those in the control group(204.64±84.76)pg/mL and(355.26±107.62)ng/mL，respectively，with the difference being of highly statistical significance(P＜0.01).Secondly，HbA1c was positively correlated with the Sost and SF levels.Thirdly，the Sost and SF levels in the T2DM group were negatively correlated with the BMD in the femoral neck and the Ward’s triangle area，but they showed no correlation with that in the L2～4 and the greater trochanter region.Conclusion The results indicated that the Sost and SF levels in elderly male patients with T2DM are notably higher than those in elderly male patients with no T2DM；the Sost and SF levels in the former are markedly negatively correlated with the BMD in the hip，which suggested that poor blood glucose control might induce increased Sost and SF levels in elderly male patients with no T2DM，thus inhibits bone formation and finally the decreases BMD in the hip.
叶燕彬 1，安荣泽 1，齐新文 1*，邝立鹏 1，陈军平 1，谢炳龙 2，钟泽填 2. 2型糖尿病老年男性患者血清铁蛋白、骨硬化蛋白与骨密度的相关性[J]. 实用骨科杂志, 2017, 23(2): 138-141.
Ye Yanbin，An Rongze，Qi Xinwen，et al. Correlation between the Serum Ferritin as well as Sclerostin and Bone Mineral Density in Elderly Male Patients with Type 2 Diabetes Mellitus. sygkzz, 2017, 23(2): 138-141.
［1］Lee RH，Pieper CF，Colon-Emeric C.Functional impairments mediate association between clinical fracture risk and type 2 diabetes mellitus in older women［J］.J Am Geriatr Soc，2015，63(8)：1546-1551.
［2］Oei L，Zillikens MC，Dehghan A，et al.High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control：the Rotterdam Study［J］.Diabetes Care，2013，36(6)：1619-1628.
［3］Heilmeier U，Carpenter DR，Patsch JM，et al.Volumetric femoral BMD，bone geometry，and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures［J］.Osteoporos Int，2015，26(4)：1283-1293.
［4］Orban E，Schwab S，Thorand B，et al.Association of iron indices and type 2 diabetes：a meta-analysis of observational studies［J］.Diabetes Metab Res Rev，2014，30(5)：372-394.
［5］Kim BJ，Ahn SH，Bae SJ，et al.Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men：a 3-year retrospective longitudinal study［J］.J Bone Miner Res，2012，27(11)：2279-2290.
［6］Li GF，Pan YZ，Sirois P，et al.Iron homeostasis in osteoporosis and its clinical implications［J］.Osteoporos Int，2012，23(10)：2403-2408.
［7］Angthong C，Angthong W，Harnroongroj T，et al.Survival times of patients with a first hip fracture with and without subsequent major long-bone fractures［J］.J Nippon Med Sch，2013，80(1)：42-49.
［8］Diamond TH，Thornley SW，Sekel R，et al.Hip fracture in elderly men：prognostic factors and outcomes［J］.Med J Aust，1997，167(8)：412-415.
［9］Kanis JA，Oden A，Johnell O，et al.The components of excess mortality after hip fracture［J］.Bone，2003，32(5)：468-473.
［10］Shepherd AJ，Cass AR，Ray LA，et al.Treatment for older men with fractures［J］.Osteoporos Int，2012，23(3)：1041-1051.
［11］中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)［J］.中国糖尿病杂志，2014，22(8)：2-42.
［12］Guariguata L.Contribute data to the 6th edition of the IDF Diabetes Atlas［J］.Diabetes Res Clin Pract，2013，100(2)：280-281.
［13］Farr JN，Khosla S.Determinants of bone strength and quality in diabetes mellitus in humans［J］.Bone，2016，59(82)：28-34.
［14］中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)［J］.中华骨质疏松和骨矿盐疾病杂志，2011，4(1)：2-17.
［15］Bartter FC，Forbes AP，Albright F.A comparison of the effect on bone formation of the hyperadrenocorticism of Cushing’s syndrome with that induced by adrenocorticotropic hormone［J］.J Clin Endocrinol Metab，1948，8(7)：592.
［16］Ardawi MS，Akhbar DH，Alshaikh A，et al.Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes［J］.Bone，2013，56(2)：355-362.
［17］Garcia Martin A，Rozas Moreno P，Reyes Garcia R，et al.Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus［J］.J Clin Endocrinol Metab，2012，97(1)：234-241.
［18］Van Campenhout A，Van Campenhout C，Lagrou AR，et al.Iron-binding antioxidant capacity is impaired in diabetes mellitus［J］.Free Radic Biol Med，2006，40(10)：1749-1755.
［19］Zarjou A，Jeney V，Arosio P，et al.Ferritin ferroxidase activity：a potent inhibitor of osteogenesis［J］.J Bone Min Res，2010，25(1)：164-172.
［20］Modder UI，Hoey KA，Amin S，et al.Relation of age，gender，and bone mass to circulating sclerostin levels in women and men［J］.J Bone Min Res，2011，26(2)：373-379.
晋公网安备 14010702070875号